Cargando…

Is tenofovir disoproxil fumarate an all-powerful weapon in the treatment of chronic hepatitis B?

Detalles Bibliográficos
Autores principales:	Kim, Ji Hoon, Lee, June Sung
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association of Internal Medicine 2015
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4293558/ https://www.ncbi.nlm.nih.gov/pubmed/25589830 http://dx.doi.org/10.3904/kjim.2015.30.1.23

Ejemplares similares

Non-Inferior Efficacy of Tenofovir Disoproxil to Tenofovir Disoproxil Fumarate in Virologically Suppressed Chronic Hepatitis B Patients
por: Yim, Hyung Joon, et al.
Publicado: (2022)

Comparative Meta-Analysis of Tenofovir Disoproxil Fumarate versus Emtricitabine and Tenofovir Disoproxil Fumarate as Treatments for Patients with Chronic Hepatitis B
por: Cui, Guangying, et al.
Publicado: (2015)

96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients
por: Liu, Zhihong, et al.
Publicado: (2023)

Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B
por: Lim, Young-Suk, et al.
Publicado: (2023)

The Administration of Tenofovir Disoproxil Fumarate for Pregnant Japanese Women with Chronic Hepatitis B
por: Suoh, Maito, et al.
Publicado: (2020)

Comparison of Pegylated Interferon Alfa Therapy in Combination with Tenofovir Alafenamide Fumarate or Tenofovir Disoproxil Fumarate for Treatment of Chronic Hepatitis B Patients
por: He, Jingjing, et al.
Publicado: (2023)

Renal Safety of Long-term Tenofovir Disoproxil Fumarate Treatment in Patients With Chronic Hepatitis B
por: Woldemedihn, Gezahegn M, et al.
Publicado: (2023)

Risk factors associated with hypophosphatemia in chronic Hepatitis B patients treated with tenofovir disoproxil fumarate
por: Lee, Dohyeong, et al.
Publicado: (2019)

Clinical Results of Tenofovir Disoproxil Fumarate in a Hemodialysis Patient with Chronic Hepatitis B
por: Aomura, Daiki, et al.
Publicado: (2020)

Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B
por: Mateos-Muñoz, Beatriz, et al.
Publicado: (2023)

Comparative pharmacokinetics between tenofovir disoproxil phosphate and tenofovir disoproxil fumarate in healthy subjects
por: Lee, Sangmi, et al.
Publicado: (2021)

Efficacy and Safety of Tenofovir Disoproxil Orotate in Chronic Hepatitis B Patients Previously Treated with Tenofovir Disoproxil Fumarate: Multicenter, Open-Label, Prospective Study
por: Chang, Young, et al.
Publicado: (2021)

Virologic breakthrough in a patient with chronic hepatitis B by combination treatment with tenofovir disoproxil fumarate and entecavir
por: Suzuki, Fumitaka, et al.
Publicado: (2014)

Seven-Year Efficacy and Safety of Treatment with Tenofovir Disoproxil Fumarate for Chronic Hepatitis B Virus Infection
por: Buti, Maria, et al.
Publicado: (2014)

Randomised clinical trial: 48 weeks of treatment with tenofovir amibufenamide versus tenofovir disoproxil fumarate for patients with chronic hepatitis B
por: Liu, Zhihong, et al.
Publicado: (2021)

Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Setting
Publicado: (2014)

Efficacy and Safety of Tenofovir Disoproxil Fumarate in Asian-Americans with Chronic Hepatitis B in Community Settings
por: Pan, Calvin Q., et al.
Publicado: (2014)

Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
por: Ha, Yeonjung, et al.
Publicado: (2020)

Effectiveness and Safety of Low Dose of Tenofovir Disoproxil Fumarate in Malagasy Patients with Chronic Hepatitis B
por: Razafindrazoto, Chantelli Iamblaudiot, et al.
Publicado: (2022)

Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B
por: Suzuki, Kazuharu, et al.
Publicado: (2022)

Converting from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Patients with Hepatitis B Following Liver Transplantation
por: Cheng, Chih-Hsien, et al.
Publicado: (2023)

Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients
por: Jung, Sang Kyung, et al.
Publicado: (2015)

Tenofovir Alafenamide Fumarate, Tenofovir Disoproxil Fumarate and Entecavir: Which is the Most Effective Drug for Chronic Hepatitis B? A Systematic Review and Meta-analysis
por: Ma, Xuefeng, et al.
Publicado: (2021)

Histopathological evaluation of long-term tenofovir disoproxil fumarate treatment in patients with hepatitis be antigen-negative chronic hepatitis B
por: Abayli, Bahri, et al.
Publicado: (2021)

Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate
por: Darmadi, Darmadi, et al.
Publicado: (2023)

Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B
por: Liao, Xingmei, et al.
Publicado: (2023)

3-year Treatment of Tenofovir Alafenamide vs. Tenofovir Disoproxil Fumarate for Chronic HBV Infection in China
por: Hou, Jinlin, et al.
Publicado: (2021)

Tenofovir-disoproxil-fumarate: Elevation in ALP: case report
Publicado: (2020)

A Review and Clinical Understanding of Tenofovir: Tenofovir Disoproxil Fumarate versus Tenofovir Alafenamide
por: Wassner, Chanie, et al.
Publicado: (2020)

Tenofovir disoproxil fumarate for multiple nucleos(t)ide analogues treatment failure hepatitis B: Is monotherapy enough?
por: Liang, Xieer, et al.
Publicado: (2022)

Short-term efficacy after switching from adefovir dipivoxil and tenofovir disoproxil fumarate therapy to tenofovir alaferamide for chronic hepatitis B
por: Sano, Tomoya, et al.
Publicado: (2021)

Real-world experience of switching from tenofovir disoproxil fumarate to tenofovir alafenamide in patients with chronic hepatitis B: a retrospective study
por: Su, Pei-Yuan, et al.
Publicado: (2021)

Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide
por: Funderburg, Nicholas T., et al.
Publicado: (2016)

Real-world impact of switching from tenofovir disoproxil fumarate to tenofovir alafenamide
por: Michienzi, Sarah M, et al.
Publicado: (2021)

Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load
por: Gordon, Stuart C, et al.
Publicado: (2013)

Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B
por: Bakhshizadeh, Fatemeh, et al.
Publicado: (2015)

Rapid Recovery in COVID-19 Patients with Chronic Hepatitis B Virus Infection Treated with Tenofovir Disoproxil Fumarate
por: Chen, Xiliu, et al.
Publicado: (2021)

Population pharmacokinetics of tenofovir given as either tenofovir disoproxil fumarate or tenofovir alafenamide in an African population
por: Kawuma, Aida N., et al.
Publicado: (2023)

Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
por: Kim, Young Min, et al.
Publicado: (2018)

Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate‐Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy
por: Bukkems, Vera E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_fsdad2ngjm8qesol35qolm8bkv